Lit­tle Cara steers through their first pos­i­tive PhI­II with a ‘break­through’ drug and a path to the FDA

7 years ago
R&D
Pharma

Atara brings on No­var­tis vet to re­place founder Ciechanover as chief

7 years ago
People
Cell/Gene Tx

‘I was shocked’: Con­tro­ver­sy brews at Emory af­ter promi­nent Chi­nese neu­ro­sci­en­tists are oust­ed over dis­clo­sure ...

7 years ago
China

Mallinck­rodt up­dates spin-off plans; FDA ex­pands Vray­lar ap­proval for Al­ler­gan; Ju­ve­nes­cence spawns Sou­vien ...

7 years ago
News Briefing

A bruised Eli Lil­ly buys rights to Cen­trex­ion's ear­ly-stage pain drug for $47.5M up­front

7 years ago
R&D

Analy­sis shows The Med­i­cines Com­pa­ny/Al­ny­lam drug in­clisir­an safe for re­nal­ly-im­paired pa­tients

7 years ago
R&D

5 cash-hun­gry biotechs crowd in­to Nas­daq in search of a $600M-plus wind­fall

7 years ago
Financing

Fac­tor VI­II lev­els con­tin­ue to drop in Bio­Marin’s 3-year up­date on he­mo­phil­ia A gene ther­a­py — but wait...

7 years ago
R&D

Brad Lon­car­'s AS­CO19 pre­view: 5 big ideas to watch for at the ul­ti­mate can­cer show of the year

7 years ago
R&D
Biotech Voices

FDA hits the red light on piv­otal tri­als at Newron, de­mand­ing new stud­ies af­ter rais­ing safe­ty con­cerns

7 years ago
R&D
FDA+

Make that 2 prospec­tive block­buster ap­provals in 1 day for No­var­tis as FDA OKs tar­get­ed can­cer ther­a­py

7 years ago
R&D

No­var­tis rolls out its next big drug at a record-set­ting price of $2.12M — let the gene ther­a­py pric­ing de­bate ...

7 years ago
R&D
Cell/Gene Tx

Akre­via scoops ex-Ar­sa­nis chief René Rus­so as CEO; Scott Got­tlieb jumps back in­to in­dus­try; Seat­tle Ge­net­ics raids ...

7 years ago
Peer Review

Project Snow White: In­ter­nal probe re­veals for­mer MiMedx C-suite spied on em­ploy­ees, lied to reg­u­la­tors and mis­led ...

7 years ago
People
Pharma

Ideaya wraps $50M IPO to fu­el clin­i­cal dri­ve on syn­thet­ic lethal­i­ty

7 years ago
Financing

Life sci­ences fund rais­es €118M for its next round of bets; Gilead scraps Alpine al­liance

7 years ago
News Briefing

Sen­ate bill to cut health costs, tar­gets FDA tweaks

7 years ago
Pharma

Trump ad­min­is­tra­tion preps ex­ec­u­tive or­der on price trans­paren­cy as law­mak­ers con­verge — WSJ

7 years ago
Pharma

Novo­cure bags mesothe­lioma nod for elec­tric fields can­cer ther­a­py with some lim­i­ta­tions

7 years ago
Pharma

A new in­ter­leukin tar­get for NASH spawns Sin­ga­pore­an biotech steered by well known play­ers

7 years ago
Startups
Discovery

Ed Kaye is tak­ing his fledg­ling biotech to Wall Street, look­ing for a new in­jec­tion of cash

7 years ago
Financing
Startups

Sobered by mount­ing costs, Dy­navax looks to un­load I/O, slash jobs and cir­cle wag­ons around Hep­lisav

7 years ago
People
R&D

Dai­ichi Sankyo re­port­ed­ly sell­ing OTC unit for $900M in piv­ot to on­col­o­gy — but com­pa­ny says it's 'in­cor­rec­t'

7 years ago
Pharma

San­thera en­ters li­cense agree­ment with Chiesi Group; Tonix's co­caine in­tox­i­ca­tion drug, Io­vance's cer­vi­cal can­cer ...

7 years ago
News Briefing
First page Previous page 946947948949950951952 Next page Last page
A service from the Financial Times